APA

Jani R. H., Gupta R., Bhatia G., Rathi G., Ashok Kumar P., Sharma R., Kumar U., Gauri L. A., Jadhav P., Bartakke G., Haridas V., Jain D. & Mendiratta S. K. (20170523). A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. : International journal of rheumatic diseases.

Chicago

Jani Rajendrakumar H, Gupta Rajiv, Bhatia Girish, Rathi Gaurav, Ashok Kumar Patnala, Sharma Reena, Kumar Uma, Gauri Liyakat A, Jadhav Praveen, Bartakke Girishchandra, Haridas Vikram, Jain Dinesh and Mendiratta Sanjeev K. 20170523. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. : International journal of rheumatic diseases.

Harvard

Jani R. H., Gupta R., Bhatia G., Rathi G., Ashok Kumar P., Sharma R., Kumar U., Gauri L. A., Jadhav P., Bartakke G., Haridas V., Jain D. and Mendiratta S. K. (20170523). A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. : International journal of rheumatic diseases.

MLA

Jani Rajendrakumar H, Gupta Rajiv, Bhatia Girish, Rathi Gaurav, Ashok Kumar Patnala, Sharma Reena, Kumar Uma, Gauri Liyakat A, Jadhav Praveen, Bartakke Girishchandra, Haridas Vikram, Jain Dinesh and Mendiratta Sanjeev K. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. : International journal of rheumatic diseases. 20170523.